. Recent reports suggest that plasma IL-6 is increased after CPB. Previous studies evaluating the influence of duration of CPB and/or aortic cross-clamp time on the release of IL-6 are conflicting.
Infusion of blood and blood products during these studies may have influenced plasma concentrations of proinflammatory cytokines by inducing host cell (monocyte) activation and IL-6 release. f he purpose of our investigation was to determine, in an environment free from blood and/or blood product administration, the influence of duration of CPB and/or aortic crossclamp on the magnitude of the IL-6 response in patients undergoing cardiac surgery. We prospectively evaluated plasma IL-6 levels preinduction (T,) and at sternal closure in 16 patients undergoing CPB (coronary artery bypass grafting, II = 9; valvular cardiac surgery, II = 7) to determine whether there is a correlation between the absolute increase in IL-6 and the duration of CPB or aortic cross-clamp time. None of the patients received blood and/or blood products during the study to control for the introduction of additional activated cells and soluble mediators, including IL-6. The results demonstrate that the magnitude of the IL-6 response to CPB is positively correlated with the duration of CPB but not with duration of aortic cross-clamp.
It seems that induction of IL-6 release is part of a normal response to CPB and does not depend on activation of host cells during prolonged aortic cross-clamp. The activation or presence of inflammatory cytokines associated with administration of blood and/or blood products could have influenced previously published investigations relating the influence of duration of CPB and/or aortic cross-clamp time to the magnitude of the IL-6 response. Implications: This study found a positive correlation between the magnitude of the interleukin 6 response to cardiopulmonary bypass and duration of cardiopulmonary bypass (but not duration of aortic cross-clamp) when measurements were made in the absence of blood/blood product transfusion. Future studies evaluating strategies to reduce cytokine responses to cardiopulmonary bypass should therefore control for cardiopulmonary bypass duration.
(Anesth Analg 1998;86:28-33) I nterleukin 6 (IL-6) is a proinflammatory cytokine expressed by a variety of cells that increases in the systemic circulation with infection, injury, or antigenie challenge. IL-6 consists of a family of at least six differentially modified phosphoglycoproteins. This cytokine is one of the key mediators of the "acute-phase response" in inflammation, a coordinated systemic response of the host to microbial invasion, inflammation, immune challenge, and tissue injury. Plasma IL-6 levels are correlated to mortality rates in sepsis (1) and have been used as a marker of systemic inflammation. Studies indicate that the increase in IL-6 observed after trauma or various surgical procedures is related to the extent of tissue injury (e.g., plasma IL-6 is greater after hip replacement than after cholecystectomy) (2). Increases in systemic plasma concentrations of IL-6 after cardiac surgery have been positively correlated with worsening left ventricular dysfunction, as defined by echocardiographic evidence of increased regional wall motion abnormality scores (3).
It is well established that a systemic inflammatory response occurs after cardiopulmonary bypass (CPB) (4). This inflammatory response is associated with the systemic release of proinflammatory cytokines, including tumor necrosis factor a! (TNF-a), interleukin 1 (IL-l), IL-6, and endotoxin. Plasma levels of the proinflammatory cytokines reported in the literature vary widely, and the mechanisms responsible for this wide range are not understood. Cremer et al. (5) demonstrated extremely large variations in IL-6 levels. Our investigation was aimed at eliminating and/or demonstrating the importance of some of these variables, which might contribute to the extreme variations reported in IL-6 levels after CPB. No study has specifically evaluated CPB duration or aortic cross-clamp duration, in an environment free from blood/blood product administration, as an independent predictor of the proinflammatory cytokine response to CPB. Studies have demonstrated significant IL-6 increases in cardiac surgical patients after CPB (6), which are thought to be the result of exposure of blood to artificial surfaces. When this occurs, activated platelets transform from a smooth discoid shape to an adherent tenticular form, and widespread capillary microembolism of fibrin-platelet aggregates occurs (7, 8) . There is associated activation of the humoral amplification system that includes induction of the coagulation cascade and activation of kallikrein, fibrinolysis, and complement cascades (9-11). Activated complement further stimulates leukocyte activation, with an associated increase in cytokine production.
The anaphylatoxins C3a and C5a, as well as the C5b-9 terminal complex, are increased above baseline levels during CPB, and this increase precedes that of IL-6 (12). Complement products have been associated with an increase in neutrophil adhesion and degranulation and have also been shown to increase production of IL-l and TNF-a, which are known to induce synthesis of IL-6 (13).
There are conflicting data regarding the increase of cytokines and their relation to the duration of CPB and/or aortic cross-clamp time (12, (14) (15) (16) (17) . One of the confounding factors that may be responsible for discrepancies in the literature is the administration of blood and/or blood products, which are known to contain increased cytokine concentrations, including . The purpose of this study was to determine whether the magnitude of the IL-6 response in cardiac surgical patients, defined as the change in the plasma concentration of IL-6 in the interval beginning immediately before induction of anesthesia (T,) and ending at the completion of sternal closure (T,), is influenced by the duration of CPB and/or aortic crossclamp, independent of the potential influence of blood and/or blood products on cytokine levels.
Methods
After obtaining institutional review board approval and written, informed consent, 23 patients were initially enrolled in this protocol. Ultimately, 16 patients undergoing CPB were evaluated. None of the study patients were receiving chronic glucocorticoid or nonsteroidal antiinflammatory drug therapy. Seven patients were removed from the study protocol because it was necessary to administer blood and/or blood products either during CPB or after CPB and before sternal closure. Of the 16 patients evaluated, 9 underwent primary coronary artery bypass grafting (CABG), whereas the other 7 underwent primary valvular cardiac surgery (VALVE). Patients enrolled in this protocol did not receive aprotinin, aminocaproic acid, or tranexamic acid therapy. Anesthetic management was standardized and consisted of induction with etomidate, sufentanil, midazolam, and vecuronium. Anesthesia was maintained with isoflurane, lorazepam, and sufentanil, with vecuronium and/or pancuronium for muscle relaxation. Fluid management consisted of plasmalyte administration 2500-4000 mL during the pre-and post-CPB periods. No salvaged blood was administered at any time during the study. CPB management was consistent for all cases. All patients underwent standard nonpulsatile hypothermic CPB to a core temperature of 28°C. Pump prime consisted of 1300-1800 mL of plasmalyte, 150-400 mL of 20% mannitol, and 5000 U of beef lung heparin. A Maxima membrane oxygenator (Medtronic Blood Systems, Inc., Anaheim, CA) was used within the extracorporeal circuit. Myocardial protection consisted of topical cooling in addition to cold, intermittent hyperkalemic crystalloid cardioplegia administered via a combination anterograde and retrograde technique. Anticoagulation was obtained by administering 300 U/kg of heparin intravenously (IV) before beginning CPB. Activated clotting time was maintained >400 s with 5000 U of heparin in incremental doses. Perfusion pressure during CPB was maintained between 50 and 70 mm Hg. A bladder temperature greater than 36°C was required before separation from CPB. If inotropic support was necessary to wean from CPB, dobutamine was used as a first-line drug, with dopamine added for additional pharmacological support as indicated. Blood samples for IL-6 measurements were obtained via an arterial line before induction (control; T,) and at the completion of sternal closure (T,), approximately 1 h after discontinuation of CPB. Samples were collected in chilled tubes containing ethylene-diamine tetraacetic acid and aprotinin. Plasma was stored at -70°C until radioimmunoassays for IL-6 (R&D Systems, Minneapolis, MN) were performed. This laboratory has extensive experience with cytokine measurement by radioimmunoassay techniques. Student's t-test was performed to test for differences between the CABG and VALVE groups with respect to uncontrolled demographic variables. Initial analysis compared IL-6 levels between the CABG and VALVE subgroups by using the Mann-Whitney u-test and the test of homogeneity of variances (F[df8,6] = 3.16, P > 0.051. Because no statistical significant difference was observed between the two groups, the groups were combined into a composite of CABG and VALVE patients. Statistical analysis was performed using Pearson's product-moment correlation to determine the degree of correlation between the absolute increase in the plasma concentration of IL-6 (AIL-6 = IL-6 [T,] -IL-6 [T,]) versus duration of CPB or aortic cross-clamp. For all statistical analysis performed, P < 0.05 was considered significant. Postoperative complications were ascertained via a review of hospital discharge summaries and the cardiothoracic surgery database.
Results
Figures 1 and 2 show the magnitude of increases in plasma concentration of IL-6 (AIL-6 = IL-6 [T,] -IL-6 [T,]) versus duration of CPB and versus duration of aortic cross-clamp, respectively. CPB times were 55-180 min with a mean + SEM of 102.4 5 8.4 min. Aortic cross-clamp times ranged from 30 to 116 min with a mean of 50.7 rfr 5.2 min. Uncontrolled demographic data are expressed in Table 1 . When the CABG and VALVE populations were compared, the only statistically significant difference was with respect to age (CABG > VALVE; P < 0.05). The type of surgical procedure performed did not influence plasma concentrations of IL-6 (F [df8,6] = 3.16, P > 0.051; therefore, data from all patients were combined to determine the influence of the duration of CPB and aortic cross-clamp on the magnitude of the IL-6 response (AIL-6 = IL-6 [T,] -IL-6 [T,]). There was a statistically significant linear correlation between the absolute increase in the plasma concentration of IL-6 and the duration of CPB (r = 0.5; P = 0.045); there was no significant relation with duration of aortic cross-clamp time (r = 0.42; P = 0.11). Figure 3 shows changes in the absolute values for IL-6 at T, and T, for each of the 16 patients. Plasma concentrations of IL-6 at T,, ranged from 0 to 21 pg/mL with a mean of 2.9 & 1.5 pg/mL. IL-6 concentrations at T, ranged from 0 to 580 pg/mL, with a mean of 149.6 + 44.1 pg/mL. The difference in the elapsed time between T, and T, ranged from 230 to 350 min. The difference in the elapsed time between discontinuation of CPB and T, ranged from 60 to 120 min. Of the 16 patients, 4 had IL-6 levels greater than 300 pg/mL at T,. These 4 patients were classified as "high" responders, whereas the other 12 were classified as "normal" responders. Table 2 outlines some differences between the high versus the normal IL-6 responders with regard to their clinical profiles. Kirklin (21) suggested that CPB causes a "whole-body inflammatory response." The sequelae from this response (e.g., fever, coagulopathy, leukocytosis, edema, and organ dysfunction) seem to worsen with increasing duration of CPB. Investigators have attempted to link the duration of CPB and/or aortic cross-clamp to the magnitude of the inflammatory response. been related to both the duration of CPB as well as to the preoperative clinical status of the patients (22,23). Because IL-6 is one of the primary mediators of the whole-body inflammatory response, we felt it important to determine whether the magnitude of release of this biochemical mediator of inflammation depends on the duration of exposure to an extracorporeal circuit and/or on the duration of aortic cross-clamp. IL-6 is the single best cytokine predictor of the adverse consequences of proinflammatory cytokine release during CPB (3,5,24). Hennein et al.
Discussion
(3) demonstrated a correlation between post-CPB left ventricular wall motion abnormality scores with increasing IL-6 and interleukin-8 plasma levels, whereas post-CPB myocardial ischemic episodes were only associated with peak IL-6 plasma concentrations.
According to previous data, IL-6 levels peak one to four hours post-CPB and remain significantly increased for up to 48 hours (25-28). In our study design, T, occurred between 60 and 120 minutes post-CPB, well within the interval of time during which IL-6 levels are known to peak. IL-6 is synthesized by monocytesl macrophages, T-lymphocytes, fibroblasts, and endothelial cells stimulated by TNF-(r and IL-l. IL-l can be released systemically during CPB. To ensure the integrity of our data, we examined the interval during which we had the greatest control of the patient's clinical management, the interval just before induction of anesthesia (To) until sternal closure (T,). We also chose ihe study interval just before onset of anesthesia until sternal closure, because previous studies (6) demonstrated no statistically significant change in IL-6 after anesthesia induction or surgical stimulation in the pre-CPB period. The absence of an initial response in this time interval may be due to the limited time between incision and initiation of CPB in most studies. Although one study reported increases in IL-6 as early as 60 minutes (29), others have suggested a more delayed response (1.5-4 hours) (2,30-32). Cruickshank et al.
(2) suggested that such a delayed response may reflect the time required for IL-6 transcription. In stimulated monocytes, an increase in IL-6 mRNA was detectable at one hour, with peak expression at three hours (33).
Is reduction of IL-6 levels and the CPB-induced inflammatory response important? The inflammatory response increases morbidity and mortality. Investigations (3, [34] [35] [36] [37] have shown that reduction of the inflammatory response is important. We have identified one variable, aortic cross-clamp time, which future studies will not need to control for when attempting to delineate factors that influence the magnitude of the IL-6 response associated with CPB. Our investigation demonstrated that the duration of aortic cross-clamp does not influence the magnitude of the IL-6 response, although it seems that there is a correlation between the duration of CPB and the magnitude of this response when blood/blood product administration are taken into account in the experimental design. The results of this investigation are important because future studies investigating therapeutic modalities that may reduce IL-6 plasma levels will need to match patients with similar CPB times but not cross-clamp times. These data suggest a link between increasing duration of CPB, with associated increased morbidity as documented by previous authors, and the magnitude of the IL-6 response. One limitation of our study could be the nonhomogeneous patient population, because we included both VALVE and CABG patients. However, our statistical analysis revealed that there was no significant influence of the type of surgical procedure on the plasma concentrations of IL-6. Inclusion of both types of surgical procedures allowed us to use a wider range of both CPB and aortic cross-clamp times to evaluate the impact of such times on the magnitude of the IL-6 response. Another limitation of our protocol could be the timing of sample point T,. As we have emphasized we examined whether the duration of CPB and/or aortic cross-clamp time affects the magnitude of the IL-6 response to CPB in an environment free from blood and/or blood product administration.
To ensure the integrity of our clinical data and to ensure that there was no contamination of our study protocol secondary to blood and/or blood product administration, the Tl measurement was obtained in the operating room before transfer to the intensive care unit.
We conclude that the magnitude of the IL-6 response, observed from the interval just before the induction of anesthesia until sternal closure, is correlated with the duration of CPB in a clinical setting in which blood and/or blood product administration was excluded from the study design. In addition, the IL-6 response to CPB is not influenced by aortic crossclamp duration. Thus, future studies evaluating therapeutic strategies that reduce the proinflammatory cytokine response to CPB need to be controlled for CPB duration but for not aortic cross-clamp duration.
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